Skip to content
Review Open access

Behavioral and sleep disorder improvement in pediatric patients with autism spectrum disorder (ASD) using extended-release melatonin (PedPRM): a systematic review

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Background: Sleep disturbances are common clinical manifestations in children with Autism Spectrum Disorder (ASD), with an estimated prevalence of 50–80%. They are characterized by sleep-onset insomnia, fragmented sleep, nighttime awakenings, and increased sleep latency. These disturbances result from alterations in the circadian rhythm, hypofunction of the suprachiasmatic nucleus (SCN), and deficient endogenous melatonin production. At the molecular level, there is reduced expression of the enzyme acetylserotonin O-methyltransferase (ASMT), responsible for converting N-acetylserotonin into melatonin, which impairs signaling through MT1/MT2 receptors and consequently affects sleep induction and maintenance. Exogenous melatonin administration, particularly in extended-release formulation (PedPRM), has been proposed as an effective adjunct pharmacological intervention. Objective: To systematically evaluate the efficacy and safety of melatonin in the treatment of sleep disturbances in children and adolescents with ASD. Methods: A structured search was conducted in the PubMed database following PRISMA 2020 guidelines and the PICOS methodological framework (Population: children/adolescents with ASD; Intervention: melatonin; Comparator: placebo; Outcomes: objective and subjective sleep parameters; Study type: RCTs). The search included publications from 2009 to 2025, in English, with full text available. Eligible studies were randomized, placebo-controlled clinical trials with exclusive pharmacological intervention using melatonin and quantitative evaluation of outcomes related to sleep, behavior, or quality of life. Six studies fully met the inclusion criteria and were analyzed. Results: Interventions ranged from 2 mg to 10 mg/day, predominantly with PedPRM, over periods of 4 to 52 weeks. Mean increases in total sleep time ranged from +57.5 min to +62.08 min, reductions in sleep latency ranged from 39.6 min to 48.6 min, greater sleep consolidation was observed (+89.1 min of continuous sleep), and reductions of up to -0.41 awakenings per night occurred. Validated scales (PSQI, CSDI, WHO-5, ESS) demonstrated behavioral and functional improvement. Tolerability was high, with occasional mild daytime sleepiness. Conclusion: Melatonin, especially PedPRM at doses of 2–10 mg/day, is a safe and effective intervention for managing sleep disturbances in ASD, providing sustained clinical benefits with relevant neurological implications for pediatric patients with Autism Spectrum Disorder (ASD).

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.